GRIN2B, which encodes a N-methyl D-aspartate (NMDA) receptor GluN2B subunit, is a target of memantine, used to treat moderate to severe dementia in patients with Alzheimer’s disease. This evidence concerns the gene GRIN2B and early-onset autosomal dominant Alzheimer disease.